Since Aβ pathology was reported to appear before tau pathology, brain atrophy, memory decline, and clinical diagnosis of AD [7, 11], determining the specific signature of soluble Aβo on the brain could also serve to develop required biomarkers to reliably detect AD before neurodegeneration produces irreversible brain damage and profound cognitive deficits. This evidence concerns the gene MAPT and Alzheimer disease.